Trial Outcomes & Findings for Symphion® System In-Office Study (NCT NCT02520414)

NCT ID: NCT02520414

Last Updated: 2021-03-26

Results Overview

Absence of device related adverse events, or death.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

10 participants

Primary outcome timeframe

2 weeks

Results posted on

2021-03-26

Participant Flow

Participant milestones

Participant milestones
Measure
Symphion®
Patients treated in-office with Symphion® Bipolar Hysteroscopic Tissue Resection System. Symphion® Bipolar Hysteroscopic Tissue Resection System
Overall Study
STARTED
10
Overall Study
COMPLETED
10
Overall Study
NOT COMPLETED
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Symphion® System In-Office Study

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Symphion®
n=10 Participants
Patients treated in-office with Symphion® Bipolar Hysteroscopic Tissue Resection System. Symphion® Bipolar Hysteroscopic Tissue Resection System
Age, Categorical
<=18 years
0 Participants
n=99 Participants
Age, Categorical
Between 18 and 65 years
10 Participants
n=99 Participants
Age, Categorical
>=65 years
0 Participants
n=99 Participants
Age, Continuous
50.4 years
STANDARD_DEVIATION 5.7 • n=99 Participants
Sex: Female, Male
Female
10 Participants
n=99 Participants
Sex: Female, Male
Male
0 Participants
n=99 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
5 Participants
n=99 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
5 Participants
n=99 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
Region of Enrollment
United States
10 participants
n=99 Participants
Body Mass Index
29.6 kg/m^2
STANDARD_DEVIATION 7.2 • n=99 Participants

PRIMARY outcome

Timeframe: 2 weeks

Absence of device related adverse events, or death.

Outcome measures

Outcome measures
Measure
Symphion®
n=10 Participants
Patients treated in-office with Symphion® Bipolar Hysteroscopic Tissue Resection System. Symphion® Bipolar Hysteroscopic Tissue Resection System
Safety Profile of the Symphion® Bipolar Hysteroscopic Tissue Resection System When Used in the Office Setting for the Removal of Intracavitary Polyps and Myomas.
Adverse Events
0 percentage of participants
Safety Profile of the Symphion® Bipolar Hysteroscopic Tissue Resection System When Used in the Office Setting for the Removal of Intracavitary Polyps and Myomas.
Device Malfunctions
0 percentage of participants

Adverse Events

Symphion®

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Meaghan Wilk Clinical Project Manager

Boston Scientific

Phone: 5086834113

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place